Audentes Therapeutics - BOLD Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00%
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$59.97 As of 01/15/2020 01:00 AM ET

+0 (0.00%)

Get New Audentes Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BOLD

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Audentes Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $59.97.

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Audentes Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/15/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/13/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/11/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/12/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/10/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/8/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/7/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/6/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/20/2020	Chardan Capital	Reiterated Rating	Hold		Low
12/16/2019	Mizuho	Reiterated Rating	Hold	$60.00	Low
12/5/2019	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$60.00	Low
12/4/2019	Chardan Capital	Reiterated Rating	Buy ➝ Neutral	$60.00	Low
12/4/2019	SVB Leerink	Downgrade	Outperform ➝ Hold	$60.00	Low
12/3/2019	Wells Fargo & Company	Lower Target	Outperform	$20.00 ➝ $19.00	N/A
12/3/2019	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A
12/3/2019	HC Wainwright	Downgrade	Buy ➝ Neutral	$60.00	N/A
12/3/2019	Mizuho	Downgrade	Buy ➝ Neutral		N/A
12/3/2019	Wedbush	Downgrade	Outperform ➝ Neutral	$60.00	N/A
12/3/2019	Citigroup	Upgrade	Sell ➝ Neutral	$30.00 ➝ $60.00	N/A
12/3/2019	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$47.00 ➝ $60.00	N/A
12/3/2019	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$55.00 ➝ $60.00	N/A
12/3/2019	Robert W. Baird	Upgrade	Underperform ➝ Neutral		N/A
12/3/2019	Guggenheim	Downgrade	Buy ➝ Neutral		N/A
11/27/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low
11/22/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$55.00	Low
11/19/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform	$40.00	High
11/11/2019	Evercore ISI	Reiterated Rating	Hold	$34.00	High
11/8/2019	HC Wainwright	Reiterated Rating	Buy	$48.00	High
10/6/2019	Chardan Capital	Reiterated Rating	Buy	$50.00	Low
10/2/2019	Robert W. Baird	Initiated Coverage	Underperform	$10.00 ➝ $10.00	Medium
9/3/2019	Chardan Capital	Boost Target	Buy	$40.00 ➝ $50.00	High
8/7/2019	Mizuho	Reiterated Rating	Buy	$45.00	High
8/7/2019	William Blair	Reiterated Rating	Hold		High
5/8/2019	HC Wainwright	Set Target	Buy	$48.00	Low
5/8/2019	BMO Capital Markets	Set Target	Buy	$47.00	Low
4/26/2019	HC Wainwright	Boost Target	Buy ➝ Buy	$44.00 ➝ $48.00	Low
4/26/2019	Citigroup	Downgrade	Neutral ➝ Sell	$28.00 ➝ $32.00	Low
4/17/2019	SVB Leerink	Boost Target	Outperform	$37.00 ➝ $48.00	High
4/9/2019	Wedbush	Boost Target	Outperform	$52.00 ➝ $57.00	Medium
4/8/2019	Piper Jaffray Companies	Boost Target	Overweight ➝ Positive	$45.00 ➝ $55.00	Low
3/18/2019	HC Wainwright	Reiterated Rating	Buy	$33.00 ➝ $44.00	Low
2/27/2019	William Blair	Reiterated Rating	Hold		High
2/25/2019	Chardan Capital	Upgrade	Neutral ➝ Buy	$35.00 ➝ $40.00	High
2/1/2019	Mizuho	Reiterated Rating	Buy	$45.00	High
1/31/2019	Cowen	Reiterated Rating	Buy		Medium
1/31/2019	William Blair	Reiterated Rating	Hold		Low
1/11/2019	HC Wainwright	Reiterated Rating	Buy	$33.00	Medium
1/11/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$35.00	High
12/10/2018	Citigroup	Lower Target	Neutral ➝ Neutral	$40.00 ➝ $28.00	Low
12/2/2018	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$23.91	High
11/26/2018	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$35.00	High
11/7/2018	Raymond James	Reiterated Rating	Hold		High
11/7/2018	B. Riley	Boost Target	Sell	$20.00 ➝ $21.00	High
11/7/2018	HC Wainwright	Set Target	Buy	$33.00	High
11/7/2018	Mizuho	Reiterated Rating	Buy	$45.00	High
11/6/2018	William Blair	Downgrade	Outperform ➝ Market Perform		High
10/14/2018	HC Wainwright	Set Target	Buy	$33.00	Low
10/9/2018	Guggenheim	Initiated Coverage	Neutral ➝ Neutral		High
10/8/2018	HC Wainwright	Set Target	Buy	$33.00 ➝ $29.00	Low
10/8/2018	Wedbush	Lower Target	Outperform ➝ Outperform	$52.00 ➝ $49.00	Low
10/5/2018	Raymond James	Reiterated Rating	Hold		Low
10/5/2018	William Blair	Reiterated Rating	Buy		High
10/3/2018	Mizuho	Reiterated Rating	Buy	$45.00	Medium
9/25/2018	HC Wainwright	Set Target	Buy	$40.00	Low
9/7/2018	Cowen	Initiated Coverage	Sell ➝ Sell	$20.00	High
9/7/2018	B. Riley	Initiated Coverage	Sell ➝ Sell	$20.00	High
8/22/2018	HC Wainwright	Set Target	Buy	$40.00	High
8/22/2018	Mizuho	Reiterated Rating	Buy	$45.00	Medium
8/20/2018	Citigroup	Initiated Coverage	Neutral	$40.00	Low
8/8/2018	Wedbush	Reiterated Rating	Outperform	$49.00	High
8/8/2018	Raymond James	Reiterated Rating	Hold		High
8/8/2018	HC Wainwright	Set Target	Buy	$40.00	High
8/8/2018	Mizuho	Upgrade	Neutral ➝ Buy	$26.00	High
8/7/2018	William Blair	Reiterated Rating	Buy		High
6/25/2018	Chardan Capital	Initiated Coverage	Neutral	$35.00	Medium
5/21/2018	Mizuho	Reiterated Rating	Neutral ➝ Hold	$38.00	Low
5/17/2018	Raymond James	Reiterated Rating	Hold		High
5/17/2018	HC Wainwright	Set Target	Buy	$40.00	High
5/17/2018	William Blair	Reiterated Rating	Buy		High
5/11/2018	Raymond James	Reiterated Rating	Hold		Medium
5/10/2018	Wedbush	Boost Target	Outperform	$49.00 ➝ $56.00	High
5/10/2018	HC Wainwright	Set Target	Buy	$37.00	High
5/2/2018	HC Wainwright	Set Target	Buy	$37.00	Low
3/9/2018	Cowen	Reiterated Rating	Buy		Low
3/9/2018	Wedbush	Reiterated Rating	Outperform	$56.00	High
3/9/2018	HC Wainwright	Set Target	Buy	$37.00	Medium
3/9/2018	William Blair	Reiterated Rating	Buy		Medium
2/12/2018	Mizuho	Initiated Coverage	Neutral ➝ Neutral	$26.00	Medium
2/7/2018	HC Wainwright	Reiterated Rating	Buy	$37.00	High

(Data available from 2/6/2018 forward)

News Sentiment Rating

1.49 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/11/2022

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/10/2022

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/9/2022

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/9/2022

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/8/2022

0 very positive mentions
0 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/8/2022

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/7/2023

1 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/6/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

No positive mentions tracked during this time.

Very Positive

forbes.com
1/13/2023
Personal And Career Success One Bold Move A Day

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Today's Range

Now: $59.97

$59.97

50 Day Range

MA: $59.97

$59.97

52 Week Range

Now: $59.97

$22.00

$60.00

Volume

N/A

Average Volume

1,504,389 shs

Market Capitalization

$2.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Audentes Therapeutics?: The following Wall Street sell-side analysts have issued reports on Audentes Therapeutics in the last twelve months:
View the latest analyst ratings for BOLD.
What is the current price target for Audentes Therapeutics?: 0 Wall Street analysts have set twelve-month price targets for Audentes Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Audentes Therapeutics in the next year.
View the latest price targets for BOLD.
What is the current consensus analyst rating for Audentes Therapeutics?: Audentes Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BOLD.
What other companies compete with Audentes Therapeutics?: Other companies that are similar to Audentes Therapeutics include Immunocore, Relay Therapeutics, Revolution Medicines, Immunovant and Beam Therapeutics. Learn More about companies similar to Audentes Therapeutics.
How do I contact Audentes Therapeutics' investor relations team?: Audentes Therapeutics' physical mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company's listed phone number is 415-818-1001 and its investor relations email address is [email protected] The official website for Audentes Therapeutics is www.audentestx.com. Learn More about contacing Audentes Therapeutics investor relations.

Audentes Therapeutics - BOLD Stock Price Target and Predictions

Analyst Price Target for BOLD

Current Consensus is N/A

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.49 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Audentes Therapeutics?

What is the current price target for Audentes Therapeutics?

What is the current consensus analyst rating for Audentes Therapeutics?

What other companies compete with Audentes Therapeutics?

How do I contact Audentes Therapeutics' investor relations team?